NasdaqCM:BLFS

Stock Analysis Report

Executive Summary

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • BioLife Solutions has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has BioLife Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.9%

NasdaqCM:BLFS

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

20.8%

NasdaqCM:BLFS

9.9%

US Medical Equipment

1.6%

US Market

BLFS outperformed the Medical Equipment industry which returned 9.7% over the past year.

BLFS outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

BLFSIndustryMarket
7 Day9.9%0.5%-0.02%
30 Day3.9%0.09%2.7%
90 Day22.3%2.0%1.4%
1 Year20.8%20.8%10.8%9.9%3.8%1.6%
3 Year1046.4%1046.4%69.0%63.9%45.2%35.8%
5 Year858.0%858.0%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is BioLife Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioLife Solutions undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioLife Solutions's share price is below the future cash flow value, and at a moderate discount (> 20%).

BioLife Solutions's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

BioLife Solutions is overvalued based on earnings compared to the US Medical Equipment industry average.

BioLife Solutions is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

BioLife Solutions is poor value based on expected growth next year.


Price Based on Value of Assets

BioLife Solutions is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is BioLife Solutions expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

55.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioLife Solutions's revenue is expected to grow significantly at over 20% yearly.

BioLife Solutions's earnings are expected to grow significantly at over 20% yearly.

BioLife Solutions's revenue growth is expected to exceed the United States of America market average.

BioLife Solutions's earnings growth is expected to exceed the United States of America market average.

BioLife Solutions's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

BioLife Solutions is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has BioLife Solutions performed over the past 5 years?

31.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioLife Solutions has delivered over 20% year on year earnings growth in the past 5 years.

BioLife Solutions has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

BioLife Solutions has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

BioLife Solutions has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

BioLife Solutions used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

BioLife Solutions has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is BioLife Solutions's financial position?


Financial Position Analysis

BioLife Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioLife Solutions's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioLife Solutions has no debt.

BioLife Solutions currently has no debt however we can't compare to 5 years ago as we have no data for that period.

BioLife Solutions has no debt, it does not need to be covered by operating cash flow.

BioLife Solutions has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

BioLife Solutions has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is BioLife Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioLife Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioLife Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioLife Solutions has not reported any payouts.

Unable to verify if BioLife Solutions's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioLife Solutions has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioLife Solutions's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Mike Rice (56yo)

13.1yrs

Tenure

US$691,397

Compensation

Mr. Michael P. Rice, also known as Mike, has been Chief Executive Officer and President of BioLife Solutions, Inc. since August 2006. Mr. Rice has more than 30 years of leadership and entrepreneurial exper ...


CEO Compensation Analysis

Mike's remuneration is lower than average for companies of similar size in United States of America.

Mike's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.6yrs

Average Tenure

57.5yo

Average Age

The tenure for the BioLife Solutions management team is about average.


Board Age and Tenure

12.0yrs

Average Tenure

57yo

Average Age

The average tenure for the BioLife Solutions board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,034,87201 Jun 19
Walter Villiger
EntityIndividual
Shares54,870
Max PriceUS$19.18
SellUS$81,27025 May 19
Roderick de Greef
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares4,500
Max PriceUS$18.06
SellUS$48,20014 Dec 18
Andrew Hinson
EntityIndividual
Role
Member of Advisory Board
Independent Director & Member of the Scientific Advisory Board
Shares4,000
Max PriceUS$12.05

Ownership Breakdown


Management Team

  • Roderick de Greef (59yo)

    CFO & Secretary

    • Tenure: 3.3yrs
    • Compensation: US$490.00k
  • Mike Rice (56yo)

    President

    • Tenure: 13.1yrs
    • Compensation: US$691.40k
  • Aby Mathew (47yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$511.00k
  • Kevin O'Donnell

    Vice President of Cold Chain Standards

    • Tenure: 4.8yrs
  • Todd Berard (50yo)

    Vice President of Marketing

    • Tenure: 4.6yrs
  • Karen Foster (59yo)

    Vice President of Operations

    • Tenure: 3.4yrs
  • Jim Mathers (60yo)

    Vice President of Global Sales

    • Tenure: 3.3yrs

Board Members

  • Ray Cohen (60yo)

    Non-Executive Chairman

    • Tenure: 5.8yrs
    • Compensation: US$240.00k
  • Thomas Girschweiler (62yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$110.00k
  • Mike Rice (56yo)

    President

    • Tenure: 13.1yrs
    • Compensation: US$691.40k
  • Shelly Heimfeld

    Member of Scientific Advisory Board

    • Tenure: 12.9yrs
  • Scott Burger

    Member of Scientific Advisory Board

    • Tenure: 12yrs
  • Dayong Gao

    Member of Scientific Advisory Board

    • Tenure: 12.9yrs
  • Joe Schick (58yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$120.00k
  • Andy Hinson (56yo)

    Independent Director & Member of the Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$115.00k
  • Erik Woods

    Member of Scientific Advisory Board

    • Tenure: 12yrs
  • Aby Mathew (47yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$511.00k

Company Information

BioLife Solutions, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioLife Solutions, Inc.
  • Ticker: BLFS
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$421.756m
  • Shares outstanding: 20.10m
  • Website: https://www.biolifesolutions.com

Number of Employees


Location

  • BioLife Solutions, Inc.
  • 3303 Monte Villa Parkway
  • Suite 310
  • Bothell
  • Washington
  • 98021
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLFSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 1989
BJX1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1989

Biography

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its pro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:35
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.